Menu

Close

Sign InSign Out

Materials

Co-pay Cards & Patient Savings Offers

Request Samples

Hospital Products

Vaccines, Biologics & ​​​​​​​Small-molecule Medicines

Pfizer Oncology Together

Pfizer RxPathways

Events

Materials

Videos

Menu

Close

Home

Efficacy

​​​​​​​Efficacy

DM

Study design

Study endpoints overview

Primary endpoint (TIS improvement)

Secondary endpoints (TIS & CDASI improvement)

cITP

Study design

Primary endpoint

Secondary endpoints

Safety & Tolerability

Safety & Tolerability

DM

Adverse reactions

cITP

Adverse reactions

Dosing & Infusion Rates  

Dosing & Infusion Rates

DM

Dosing and administration

Infusion rate chart

​​​​​​​Infusion rate calculator

cITP

Dosing and administration

Infusion rate chart

Infusion rate calculator

About

About

National Insurance Coverage

Storage and handling

Vial sizes and NDC numbers

Biochemical composition and manufacturing

Support

Support

Materials & videos

Ig Companion

Frequently asked questions

Request a representative

Efficacy

​​​Dermatomyositis (DM)

DM
Study design
DM
​​​​​​​Study endpoints overview
DM
​​​​​​​Primary endpoint (TIS improvement)
DM
​​​​​​​Secondary endpoints (TIS & CDASI improvement)

After patients switched from placebo to OCTAGAM 10%, both treatment arms achieved similar mean TIS at 10 months1

At 4 months, there were greater improvements in mean TIS in the OCTAGAM 10% arm vs placebo arm1

Card Header

Header

This text is for block level content. P tags can go in here too

Header

This text is for block level content. P tags can go in here too

Header

This text is for block level content. P tags can go in here too

  •  Mean TIS is a secondary endpoint which is different than the primary endpoint of TIS responder rate1*† ​​​​​​​
 
*Mean TIS is defined as the average TIS values collected from baseline to week 16, then at week 28 and week 40.
TIS responder rate is the proportion of patients achieving a TIS improvement of ≥20 points (at least minimal improvement), ≥40 points (at least moderate improvement), ≥60 points (major improvement).

** This is an optional area where footnotes can live.

After patients switched from placebo to OCTAGAM 10%, both treatment arms achieved similar mean CDASI total activity scores at 10 months1

At 4 months, there were greater improvements in mean CDASI total activity score in the OCTAGAM 10% arm vs placebo arm2

Card Header

Header

This text is for block level content. P tags can go in here too

Header

This text is for block level content. P tags can go in here too

Header

This text is for block level content. P tags can go in here too

  •  A greater improvement in mean CDASI total activity score was demonstrated with OCTAGAM 10% vs placebo at 4 months (mean change -9.4 vs -1.2)1,2
  • In the open-label extension period, patients who switched to OCTAGAM 10% achieved a similar mean CDASI total activity score vs patients who received OCTAGAM 10% throughout the entire study1
  • CDASI total activity scores of ≥15 indicate moderate-to-severe skin disease3,4 
  • In clinical studies, the target treatment difference between the study drug and placebo arms is a 5- to 10-point change from baseline4

*The CDASI Total Activity Score ranges from 0-100.5

Learn more about CDASI endpoint

** This is an optional area where footnotes can live.


 References
  1. Data on file. Octapharma USA Inc. 
  2. OCTAGAM 10% [prescribing information]. Paramus, NJ: Octapharma USA Inc.; 2021. 
  3. Ahmed S, Chen KL, Werth VP. The validity and utility of the Cutaneous Disease Area and Severity  Index (CDASI) as a clinical outcome instrument in dermatomyositis: a comprehensive review. Semin  Arthritis Rheum. 2020;50(3):458-462. 
  4. Brevard JA, Hurtt M, Horobin J, et al. Design considerations for clinical trials using the Cutaneous Dermatomyositis Disease Area and Severity Index as a primary endpoint. J Clin Exp Dermatol Res.  2017;8(4). doi:10.4172/2155-9554.1000401​​​​​​​​​​
  5. Tiao J, Feng R, Bird S, Choi JK, et al. The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists. Br J Dermatol. 2017;176(2):423-430. doi:10.1111/bjd.15140

 
DM safety and tolerability data 
for OCTAGAM 10%

 

Administration Video

Review data

DM dosing and infusion rates 
for OCTAGAM 10%

Resources for patients and HCPs

See details 

 
OCTAGAM 10% DM clinical 
results video
 

Resources for patients and HCPs

Watch here 

WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE

  • Thrombosis may occur with immune globulin intravenous (IgIV) products, including OCTAGAM 10% liquid. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IgIV products, including OCTAGAM 10% liquid. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IgIV products containing sucrose. OCTAGAM 10% liquid does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer OCTAGAM 10% liquid at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Dosing and Administration
Patients with dermatomyositis are at increased risk for thromboembolic events; monitor carefully and do not exceed an infusion rate of 0.04 mL/kg/min.

Contraindications
OCTAGAM 10% liquid is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.

Warnings and Precautions
OCTAGAM 10% liquid may cause hypersensitivity in patients with a corn allergy. OCTAGAM 10% liquid contains maltose, which is derived from corn.

Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure.

Falsely elevated blood glucose readings may occur during and after the infusion of OCTAGAM 10% liquid with testing by some glucometers and test strip systems.

Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving OCTAGAM 10% liquid.

Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to treatment with OCTAGAM 10% liquid. Risk factors for hemolysis include high doses and non–O-blood group. Closely monitor patients for hemolysis and hemolytic anemia.

Aseptic meningitis syndrome may occur in patients receiving OCTAGAM 10% liquid, especially with high doses or rapid infusion.

Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]).

OCTAGAM 10% liquid is made from human plasma and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent.

Adverse Reactions
cITP - The most common adverse reactions reported in >5% of study subjects were headache, fever, and increased heart rate.

DM - The most common adverse reactions reported in >5% of study subjects were headache, fever, nausea, vomiting, increased blood pressure, chills, musculoskeletal pain, increased heart rate, dyspnea, and infusion site reactions.

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only).  If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
​​​​​​​

OCTAGAM® is a registered trademark of Octapharma AG.

Please click here for Full Prescribing Information, including BOXED WARNING.

OCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults.

INDICATIONs and Usage

OCTAGAM® 10% [Immune Globulin Intravenous (Human)] liquid is indicated for the treatment of chronic immune thrombocytopenic purpura (cITP) to rapidly raise platelet counts to control or prevent bleeding in adults and for dermatomyositis (DM) in adults.

Please click here for Full Prescribing Information, including BOXED WARNING.

    Please see full Prescribing Information, including BOXED WARNING.

    OK. We'll need you to sign in before we can determine if you are aligned with a sales  representative. 

    If you select 'Yes', you will be required to enter your username and password in the sign-in form that will appear over this window.

    Would you like to sign in now?